ALB MANUFACTURE

CORPORATE & STRATEGIC PARTNERSHIP PROPOSAL

ONE HEALTH BIOPHARMA

INNOVATION PLATFORM


BY ALB MANUFACTURE

Natural bioactive technology for scalable human-health solutions.

PREPARED FOR EUROPEAN PHARMACEUTICAL DISTRIBUTION PARTNERS

CONFIDENTIAL CORPORATE PRESENTATION

SEPTEMBER 2026



THE PARTNERSHIP THESIS

A Technology Platform Built for European Partnership

Alb Manufacture offers European distributors an immediate route to a differentiated commercial opportunity, together with structured access to an expanding Human BioPharma portfolio.



ONE RELATIONSHIP.

EXPANDING VALUE.

NEAR-TERM COMMERCIAL ENTRY

A market-ready flagship supported by production, documentation and partner onboarding.

LONG-TERM PORTFOLIO GROWTH

Structured access to pipeline assets, co-development opportunities and regional expansion.

CORPORATE IDENTITY

WHO WE ARE

Alb Manufacture SH.P.K. is an Albanian One Health BioPharma development company transforming natural bioactive resources and scientific know-how into scalable human-health technologies.

ALBANIAN ORIGIN.

INTERNATIONAL AMBITION.

ONE COMPANY / THREE CORE ROLES

We build at the intersection of natural active systems, formulation science and industrial execution.

01

BIOPHARMA DEVELOPER

We originate and structure Human BioPharma platforms, formulations and development pathways.

02

TECHNOLOGY OWNER

We create proprietary know-how across extraction, standardization and formulation.

03

INDUSTRIAL OPERATOR

We translate innovation into manufacturable, transferable and commercially scalable solutions.

OUR STRATEGIC POSITIONING

Integrated by design. Distinct in the market.

The BioPharma value chain is commonly divided among specialized roles. Alb Manufacture is structured to connect them within one expandable platform.

	ORIGIN INTELLIGENCE	PROPRIETARY TRANSFORMATION	PORTFOLIO DEVELOPMENT	PARTNER DEPLOYMENT
RESOURCE-LED MODEL Natural-resource supply	PRIMARY FOCUS			
TECHNICAL-SERVICE MODEL Extraction or formulation services		PRIMARY FOCUS		
BRAND-LED MODEL Finished-product commercialization			PRIMARY FOCUS	
ALB MANUFACTURE Integrated One Health BioPharma model	INTEGRATED	INTEGRATED	INTEGRATED	INTEGRATED

One company architecture. Multiple pathways to market.


OUR ONE HEALTH BIOPHARMA VISION

Human health is part of a living system.

Our vision connects natural resources and the biological continuum of geology, soil, water, plants, animals and humans with biotechnology, formulation science and modern Human BioPharma development.

FROM NATURAL INTELLIGENCE

TO MODERN BIOPHARMA SOLUTIONS



INTERCONNECTED BIOLOGICAL CONTINUUM

OUR DEVELOPMENT PRINCIPLE

Broad biological intelligence. Focused Human BioPharma development.

FROM NATURAL RESOURCES TO BIOPHARMA SOLUTIONS

A repeatable pathway from natural complexity to partner-ready value.

Alb Manufacture applies a structured development logic that converts selected natural matrices into differentiated BioPharma assets.

INPUTS

SELECTED NATURAL SYSTEMS

- Geological bioactive matrices
- Botanical and polyphenol-rich resources
- Naturally occurring active systems

PROPRIETARY TRANSFORMATION

A controlled sequence designed to preserve functional value and create reproducible specifications.

01	CHARACTERIZE	02	RECOVER	03	SEPARATE
04	STANDARDIZE	05	FORMULATE	06	SCALE

OUTPUTS

BIOPHARMA ASSETS

- Natural active ingredients
- Standardized extracts
- Delivery platforms
- Finished human-health solutions

THE END-TO-END VALUE CHAIN

SOURCE > EXTRACTION > ACTIVE INGREDIENT > FORMULATION > FINISHED PRODUCT > MARKET

One controlled architecture connects scientific transformation with commercial deployment.

A RARE GEOLOGICAL ASSET

Not simply a natural source. A time-formed geological asset.

~85 MILLION YEARS

APPROXIMATE GEOLOGICAL AGE

The mineral-organic matrix originates from a geological formation approximately 85 million years old, found within underground galleries in northeastern Albania.



GEOLOGICAL STRATIFICATION

INDUSTRIAL ACCESS CONTEXT

DIFFERENTIATED ORIGIN

LOCAL GEOLOGICAL PROVENANCE

ORIGIN CREATES DIFFERENTIATION. **TECHNOLOGY CREATES REPRODUCIBLE VALUE.**

OUR PROPRIETARY KNOW-HOW

Know-how is the core asset.

The value is encoded in process sequence, operating parameters, specification logic and transferability - not in raw-material access alone.

01

SOURCE & MATRIX INTELLIGENCE

Selection, characterization and fit-for-purpose assessment.

02

CONTROLLED BIOACTIVE RECOVERY

Process logic designed around functional-value preservation.

03

SEPARATION & RISK CONTROL

Filtration, purification and contaminant-control pathways.

04

STANDARDIZATION & FORMULATION

Specification development and reproducible product design.

05

SCALE-UP & TECHNOLOGY TRANSFER

Translation from proprietary method to industrial execution.

CONFIDENTIAL PROCESS INTELLIGENCE

PROTECTED / REPEATABLE / TRANSFERABLE

INTEGRATED TECHNOLOGY PLATFORMS

A connected technology core - from recovery to delivery.

Each platform can support proprietary products, partner formulations or technology-transfer programs.

01 **BIOACTIVE RECOVERY**

Humic, fulvic, botanical and polyphenol extraction platforms.

CURRENT CORE + DEVELOPMENT

02 **PURIFICATION & STANDARDIZATION**

Separation, analytical specification and planned purification scale-up.

PLANNED INDUSTRIALIZATION

03 **FORMULATION SYSTEMS**

Functional ingredient systems, liquid formulations and product adaptation.

ACTIVE DEVELOPMENT

04 **ADVANCED DELIVERY**

Liposomal, nano-emulsion, microencapsulation and water-soluble systems.

STRATEGIC DEVELOPMENT

Modular platforms. Multiple product pathways. Flexible partner integration.

HUMAN BIOPHARMA PORTFOLIO

One portfolio. Six interconnected layers.

The architecture enables partners to enter at the ingredient, platform, product or commercialization level.

MULTIPLE ENTRY POINTS

ONE STRATEGIC SYSTEM

01 **NATURAL ACTIVE INGREDIENTS & API DEVELOPMENT**

High-value natural actives and development pathways toward standardized APIs.

02 **STANDARDIZED EXTRACTS & FUNCTIONAL INGREDIENTS**

Partner-ready ingredient systems for differentiated formulations.

03 **ADVANCED DELIVERY TECHNOLOGIES**

Solubilization, encapsulation and bioactive-protection platforms.

04 **CLINICAL DEVELOPMENT PLATFORMS**

Science-led concepts organized around defined human-health areas.

05 **FINISHED HUMAN-HEALTH SOLUTIONS**

Commercial, near-commercial and development-stage formulations.

06 **TECHNOLOGY TRANSFER & GLOBAL PARTNERSHIPS**

Licensing, CMO, co-development and regional commercialization.

PORTFOLIO DEPTH & DEVELOPMENT READINESS

A broad pipeline, structured by development maturity.

100+

STRATEGIC PIPELINE ASSETS

Across active ingredients, standardized extracts, delivery systems, clinical platforms and finished formulations.

15+
CLINICAL DEVELOPMENT PLATFORMS

20+
NATURAL ACTIVE INGREDIENTS

30+
STANDARDIZED EXTRACTS

15+
ADVANCED DELIVERY SYSTEMS

50+
FINISHED FORMULATION CONCEPTS

READINESS SIGNALS

1 active market product / 2 full clinical-platform dossiers / broader framework and concept pipeline

PRIORITY HUMAN-HEALTH AREAS

Focused on high-relevance biological systems.

Portfolio development is organized around interconnected health areas rather than isolated product categories.

01 **GASTROINTESTINAL & MICROBIOME**

Gut environment, barrier and microbiome-centered development.

02 **METABOLIC & MITOCHONDRIAL**

Metabolic balance, energy systems and weight-management concepts.

03 **CARDIOVASCULAR & ENDOTHELIAL**

Cardiometabolic and vascular-support development platforms.

04 **HEPATIC SUPPORT**

Liver-support and metabolic-clearance development systems.

05 **IMMUNE RESILIENCE**

Immune-support and seasonal respiratory wellness concepts.

06 **REDOX BALANCE**

Oxidative-balance and cellular-protection development platforms.

07 **HEALTHY AGING & CELLULAR RESILIENCE**

Longevity and whole-system resilience concepts.


ADJACENT DEVELOPMENT AREAS

NEUROCOGNITIVE & GUT-BRAIN / CONNECTIVE TISSUE & PHYSIOLOGICAL RECOVERY

SCALABLE MANUFACTURING MODEL

A defined path from current output to partner-enabled scale.

Capacity expansion is structured through in-house optimization, modular growth and qualified manufacturing partnerships.



FOUR SCALE LEVERS

01	IN-HOUSE OPTIMIZATION
02	MODULAR CAPACITY EXPANSION
03	QUALIFIED GMP / CMO PATHWAY
04	TECHNOLOGY TRANSFER

Scale is activated against validated demand and the selected partner model.

Target capacity depends on industrial expansion and/or contract-manufacturing activation.

QUALITY & COMPLIANCE ARCHITECTURE

Two current certifications. One controlled operating foundation.

Alb Manufacture is independently assessed for food-safety management and current good manufacturing practice within its certified scope.

ISO 22000:2018

FOOD SAFETY MANAGEMENT SYSTEMS

Design, production and sale of food supplements for human and animal use; related certified scope.

CERTIFICATE NO. SMSU20251013ALAM

GMP

CURRENT GOOD MANUFACTURING PRACTICE

Manufacturing, packaging, labelling or holding of dietary supplements within the certified scope.

CERTIFICATE NO. GMP20251013ALAM

QUALITY CONTROL	RAW MATERIALS / PROCESS CONTROL / ANALYTICAL TESTING / BATCH RECORDS / STABILITY / TRACEABILITY
MARKET READINESS	TECHNICAL DOSSIER / LABEL REVIEW / CLAIMS CONTROL / MARKET-SPECIFIC REGULATORY ADAPTATION

Certification body: e-Cert. Certification status remains subject to continued system maintenance and supervisory audits.

WHY PARTNER WITH ALB MANUFACTURE

A differentiated entry point - with value that expands over time.

The partnership combines near-term commercial execution with privileged access to proprietary know-how and a developing Human BioPharma portfolio.

01

CATEGORY DIFFERENTIATION

A distinctive origin, process narrative and product architecture beyond commodity supplementation.

02

TERRITORIAL VALUE

Market structures can protect committed partners through defined geography, channels and performance terms.

03

KNOW-HOW ACCESS

Direct access to technical onboarding, product intelligence and selected technology pathways.

04

PORTFOLIO EXPANSION

A relationship designed to grow from one commercial entry point into additional categories.

05

SCALABLE EXECUTION

Phased capacity activation aligned with validated demand, compliance and partner forecasts.

PARTNER OUTCOME

A defensible market position today - and a structured innovation pipeline for tomorrow.

NEAR-TERM COMMERCIAL ENTRY

From agreement to market activation through one coordinated launch pathway.

The current market-ready flagship creates an immediate starting point while Alb Manufacture supports the distributor across technical, regulatory and commercial preparation.

01

MARKET & REGULATORY REVIEW

Country classification, claims, label and route-to-market requirements.

02

PARTNER ONBOARDING

Technical dossier, product training, positioning and scientific-commercial materials.

03

SUPPLY & LAUNCH

Forecast alignment, initial order, production scheduling and controlled market introduction.

04

PERFORMANCE GOVERNANCE

Reorder cadence, channel feedback, demand signals and next-category selection.

ALB MANUFACTURE PROVIDES DOCUMENTATION / TRAINING / MARKET ADAPTATION / SUPPLY COORDINATION / LAUNCH SUPPORT

FROM PRODUCT ENTRY TO PORTFOLIO VALUE

The relationship is designed to compound - not stop at distribution.

Partners may gain structured access to additional formulations, development platforms and commercialization rights as technical readiness and market evidence progress.

01

PORTFOLIO ACCESS

Selected new formulations and category extensions aligned with territory needs.

02

CO-DEVELOPMENT

Joint product definition, localization, validation planning and launch architecture.

03

RIGHTS & LICENSING

Defined access to formulations, technology or commercialization rights where appropriate.

04

REGIONAL INDUSTRIALIZATION

CMO activation, qualified manufacturing or technology-transfer pathways at scale.

LONG-TERM PRINCIPLE

Commercial performance unlocks deeper portfolio participation and regional value creation.

ONE PLATFORM / MULTIPLE ENTRY MODELS

The partnership structure adapts to territory, capability and ambition.

Each model is defined through clear commercial rights, technical responsibilities, quality requirements and performance milestones.

01 **DISTRIBUTION**

Commercial launch and channel development within an agreed market.

02 **EXCLUSIVE TERRITORY**

Conditional territorial protection linked to forecasts, investment and performance.

03 **CO-DEVELOPMENT**

Jointly designed products or market-specific adaptations.

04 **LICENSING**

Defined use of selected formulation or technology rights.

05 **REGIONAL MANUFACTURING**

Qualified CMO, private-label or technology-transfer execution.

MODEL SELECTION **TERRITORY / REGULATORY ROUTE / FORECAST / CAPABILITY / INVESTMENT / GOVERNANCE**

THE FIRST COMMERCIAL EXPRESSION OF OUR TECHNOLOGY

DR. NATURE

A standardized liquid humic-fulvic matrix developed through controlled low-temperature extraction.

COMMERCIAL FLAGSHIP

LIQUID BIOACTIVE MATRIX

50 ML



FROM PROPRIETARY PROCESS TO MARKET-READY PRODUCT

PRODUCT IDENTITY & TECHNICAL PROFILE

One liquid formulation. A defined analytical identity.

50 ml	58 g/L	45 g/L	8.5	0
ORAL LIQUID	HUMIC ACIDS	FULVIC ACIDS	REFERENCE pH	ADDED PRESERVATIVES

DOSAGE FORM

Dark, homogeneous, water-dispersible liquid.

PACKAGING

50 ml amber-glass bottle with precision dropper.

PROCESS BASIS

Demineralized water and controlled alkaline extraction.

DAILY ROUTINE

Label-directed use: 3 ml diluted in 150-200 ml water.

STORAGE PROFILE

Protected from light; recommended storage 5-25°C.

PRODUCT CATEGORY

Food supplement; market-specific regulatory review required.

Primary composition values reflect current product analytical documentation; final market presentation remains subject to applicable local requirements.

FROM AN ANCIENT GEOLOGICAL MATRIX TO DR. NATURE

Origin is not decoration. It is the starting specification.

The product begins with a mineral-organic matrix formed approximately 85 million years ago and accessed through underground galleries in northeastern Albania.

~85 MILLION YEARS

APPROXIMATE GEOLOGICAL AGE

01 ORIGIN IDENTITY

Approx. 85 million years
Northeastern Albania
Time-formed mineral-organic matrix

02 CONTROLLED RECOVERY

Selective raw-material qualification
Demineralized-water extraction
Low-temperature preservation and purification

03 LIQUID SPECIFICATION

Defined humic-fulvic profile
Standardized batch controls
Market-ready liquid format

TRACEABLE CONTINUITY ORIGIN > RECOVERY > SPECIFICATION

THE LOW-TEMPERATURE EXTRACTION PROCESS

A controlled sequence converts geological complexity into a repeatable liquid specification.

Each step has a distinct purpose: recover the target matrix, reduce variability, control contaminants and prepare a consistent finished product.

01 SELECT
Qualified raw material

02 PREPARE
Demineralized water

03 EXTRACT
Controlled alkaline medium

04 PRESERVE
Approx. 37°C; below 40°C

05 PURIFY
Undesirable contaminant control

06 FILTER
Solid-liquid separation

07 STABILIZE
pH and matrix homogenization

08 RELEASE
Fill, label, lot and final controls

PROCESS OBJECTIVE PRESERVE FUNCTIONAL VALUE / CONTROL VARIABILITY / DELIVER REPRODUCIBLE BATCHES

WHY 37°C CHANGES THE PRODUCT

Low temperature protects what intensive heat can alter.

37°C

APPROXIMATE CONTROLLED PROCESS TEMPERATURE

The extraction is maintained within a documented limit below 40°C, avoiding aggressive thermal exposure and dehydration.

PRESERVED STRUCTURE

Carboxyl, hydroxyl, phenolic and quinone functional domains remain structurally available within the liquid matrix.

PRESERVED INTERACTION POTENTIAL

The finished matrix retains sites capable of familiar binding, buffering, complexation and electron-exchange interactions.

PRESERVED BIOACTIVE IDENTITY

The product reaches the user as a functionally preserved liquid matrix - not as an intensively heat-processed residue.

THE DIFFERENCE — **The process is designed to conserve the matrix before standardizing the product.**


A BIOACTIVE MATRIX - NOT AN ISOLATED MOLECULE

Molecular diversity is part of the functional architecture.

Humic substances are heterogeneous molecular systems. Their behavior arises from the relationship among multiple fractions and functional domains.

FUNCTIONAL CONSEQUENCE

The balance of fractions and functional groups shapes binding, buffering, redox and mineral-complexation behavior. Source control and process control therefore matter together.



FOUR LEVELS OF BIOLOGICAL INTERACTION

The rationale begins at biological interfaces - not with a therapeutic claim.

The preserved matrix offers multiple physicochemical interaction pathways that can be evaluated through evidence-led nutritional and clinical development.

01 **GASTROINTESTINAL INTERFACE**

Humic fractions act primarily within the intestinal environment, where functional groups can interact with selected organic compounds and ions.

02 **REDOX BALANCE**

Phenolic and quinone domains can participate in reversible electron exchange within the matrix.

03 **MINERAL COMPLEXATION**

Water-soluble fulvic fractions can form complexes with mineral ions, supporting mobility in aqueous environments.

04 **MICROBIOME & BARRIER SUPPORT**

The intestinal ecosystem, barrier integrity and immune signalling form an interconnected field for continued scientific evaluation.

SCIENTIFIC POSITIONING **EVIDENCE-LED NUTRITIONAL SUPPORT / NO THERAPEUTIC CLAIMS / MARKET-SPECIFIC CLAIMS REVIEW**

FROM VALIDATED ENTRY TO PARTNER-ENABLED SCALE

One product to enter. One platform to expand.

Commercial scale is activated through a defined territory, an agreed forecast and a coordinated regulatory and launch plan.

30,000
UNITS / YEAR
CURRENT CAPACITY

PHASED SCALE-UP

300,000
UNITS / YEAR
TARGET CAPACITY

PARTNERSHIP ACTIVATION

01 DEFINE TERRITORY
02 CONFIRM REGULATORY PATH
03 ALIGN ANNUAL FORECAST
04 AGREE LAUNCH CALENDAR

STRATEGIC NEXT STEP Define the market, the model and the first execution milestone.

OFFICIAL CONTACT ALB MANUFACTURE SH.P.K. | LUSHNJE, ALBANIA | +355 69 393 5395
albmanufacture.com | drnatureremedies.com | info@albmanufacture.com | albmanufacture@gmail.com